Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD
NCT ID: NCT02386735
Last Updated: 2025-03-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
NA
Total Enrollment
133 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-03-31
Study Completion Date
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background
Chronic obstructive pulmonary disease (COPD) is a major public health issue with no curative treatment. In Switzerland estimated 5-7% of the total population are suffering from this chronic disease. According to current guidelines corticosteroids are part of treatment of acute exacerbations in COPD patients. Several studies suggest that corticosteroids accelerate the recovery of forced expiratory volume in 1 second (FEV1), decrease duration of hospitalization, reduce treatment failure rate and improve clinical outcome. The additional therapeutic benefit on FEV1-recovery tough seems only to last for three to five days. The investigators recently published a hospital-based study showing that in patients presenting to emergency departments with acute exacerbation of COPD, a short five day treatment with systemic steroids was not inferior to a conventional 14 day treatment with regard to re-exacerbation. Cumulative corticosteroid dose could be reduced in this trial. To the investigators knowledge no data is available about the minimal necessary corticosteroid dose in an outpatient treatment setting so far.
Aim
The primary aim of this study is to investigate in an outpatient setting, whether a three day treatment with orally administered systemic corticosteroids is non-inferior to a five day treatment in acute exacerbation of COPD and if total glucocorticoid exposure can be reduced by shorter therapy.
Hypothesis
The investigators postulate, that in an outpatient setting, where generally less severe exacerbations are being treated, a three day treatment duration of systemic corticosteroids should be non-inferior to a five day treatment duration with regard to treatment benefits but decrease cumulative corticosteroid exposure.
Design and Setting
This study is going to be performed as a prospective, randomized, double-blind, placebo-controlled, non-inferiority trial in an outpatient setting. Randomization will be performed as block randomization with a 1:1 allocation. The investigators are going to recruit GPs in northwestern and central Switzerland.
Methods
The investigators are going to include patients presenting to GP's with acute exacerbation of COPD. When matching the investigators eligibility criteria and written informed consent is given, patients included in the study are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for either five days (conventional arm) or three days (interventional arm) followed by two days of placebo for the interventional group. Pre-randomized, identically looking, numbered blisters are given to all patients included in the study. Antibiotic treatment (Amoxicillin/Clavulanic acid, 625mg 3/d, for ten days) is given to all patients with a CRP ≥50mg/l, COPD and known diagnosis of bronchiectasis, as well as patients presenting with all three of the following symptoms: change of baseline dyspnea, change of sputum quantity and sputum purulence. Further initial treatment and steroid treatment after inclusion is determined and documented by the GP. Patients will undergo follow-up visits at day three and seven by their GP as well as follow-up phone calls executed by the study center at day 30, 90 and 180.
Chronic obstructive pulmonary disease (COPD) is a major public health issue with no curative treatment. In Switzerland estimated 5-7% of the total population are suffering from this chronic disease. According to current guidelines corticosteroids are part of treatment of acute exacerbations in COPD patients. Several studies suggest that corticosteroids accelerate the recovery of forced expiratory volume in 1 second (FEV1), decrease duration of hospitalization, reduce treatment failure rate and improve clinical outcome. The additional therapeutic benefit on FEV1-recovery tough seems only to last for three to five days. The investigators recently published a hospital-based study showing that in patients presenting to emergency departments with acute exacerbation of COPD, a short five day treatment with systemic steroids was not inferior to a conventional 14 day treatment with regard to re-exacerbation. Cumulative corticosteroid dose could be reduced in this trial. To the investigators knowledge no data is available about the minimal necessary corticosteroid dose in an outpatient treatment setting so far.
Aim
The primary aim of this study is to investigate in an outpatient setting, whether a three day treatment with orally administered systemic corticosteroids is non-inferior to a five day treatment in acute exacerbation of COPD and if total glucocorticoid exposure can be reduced by shorter therapy.
Hypothesis
The investigators postulate, that in an outpatient setting, where generally less severe exacerbations are being treated, a three day treatment duration of systemic corticosteroids should be non-inferior to a five day treatment duration with regard to treatment benefits but decrease cumulative corticosteroid exposure.
Design and Setting
This study is going to be performed as a prospective, randomized, double-blind, placebo-controlled, non-inferiority trial in an outpatient setting. Randomization will be performed as block randomization with a 1:1 allocation. The investigators are going to recruit GPs in northwestern and central Switzerland.
Methods
The investigators are going to include patients presenting to GP's with acute exacerbation of COPD. When matching the investigators eligibility criteria and written informed consent is given, patients included in the study are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for either five days (conventional arm) or three days (interventional arm) followed by two days of placebo for the interventional group. Pre-randomized, identically looking, numbered blisters are given to all patients included in the study. Antibiotic treatment (Amoxicillin/Clavulanic acid, 625mg 3/d, for ten days) is given to all patients with a CRP ≥50mg/l, COPD and known diagnosis of bronchiectasis, as well as patients presenting with all three of the following symptoms: change of baseline dyspnea, change of sputum quantity and sputum purulence. Further initial treatment and steroid treatment after inclusion is determined and documented by the GP. Patients will undergo follow-up visits at day three and seven by their GP as well as follow-up phone calls executed by the study center at day 30, 90 and 180.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in China
NCT03633838
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
COMPLETED
Dose of Corticosteroids in COPD
NCT01742338
COPD
TERMINATED
PHASE4
Corticosteroid Reduction in COPD
NCT02857842
Lung Diseases, Obstructive
Blood Eosinophil Count
Glucocorticoids
+2 more
COMPLETED
PHASE4
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
NCT00975195
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE4
Stratified TreAtment to Reduce Risk in COPD
NCT04458636
COPD Exacerbation
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pulmonary Disease, Chronic Obstructive
Adverse Effect of Glucocorticoids and Synthetic Analogues
Disease Exacerbation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Investigational treatment
Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
Group Type
EXPERIMENTAL
Placebo
Intervention Type
DRUG
Three days prednisone 40mg, two days placebo
Standard treatment
Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.
Group Type
ACTIVE_COMPARATOR
Prednisone
Intervention Type
DRUG
Five days prednisone 40mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Three days prednisone 40mg, two days placebo
Intervention Type
DRUG
Prednisone
Five days prednisone 40mg.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed Consent as documented by signature
* Age ≥40 years
* History of ≥10 pack-years of smoking (past or present smokers)
* Airway obstruction, defined as FEV1/FVC≤70%
* Current acute exacerbation of COPD by clinical criteria, defined by the presence of at least two of the following:
* Change of baseline dyspnea
* Change of cough
* Change of sputum quantity or purulence
* Age ≥40 years
* History of ≥10 pack-years of smoking (past or present smokers)
* Airway obstruction, defined as FEV1/FVC≤70%
* Current acute exacerbation of COPD by clinical criteria, defined by the presence of at least two of the following:
* Change of baseline dyspnea
* Change of cough
* Change of sputum quantity or purulence
Exclusion Criteria
* Diagnosis of asthma
* Initial necessity of hospitalization
* Women who are pregnant or breast feeding
* Premenopausal women with insufficient contraception and anamnestic risk for pregnancy
* Severe coexisting disease with life expectancy \<6 months
* Diagnosis of tuberculosis
* Known severe immunosuppression or immunosuppression after solid organ or stem cell transplantation
* Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
* Participation in another study involving an investigational drug
* Previous enrolment into the current study
* Initial necessity of hospitalization
* Women who are pregnant or breast feeding
* Premenopausal women with insufficient contraception and anamnestic risk for pregnancy
* Severe coexisting disease with life expectancy \<6 months
* Diagnosis of tuberculosis
* Known severe immunosuppression or immunosuppression after solid organ or stem cell transplantation
* Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
* Participation in another study involving an investigational drug
* Previous enrolment into the current study
Minimum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut für Hausarztmedizin Basel
UNKNOWN
Sponsor Role
collaborator
Kantonsspital Baselland Bruderholz
OTHER
Sponsor Role
collaborator
Prof. Dr. Jörg Leuppi
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Jörg Leuppi
Prof. Dr. med.
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joerg D. Leuppi, Prof.
Role: PRINCIPAL_INVESTIGATOR
Kantonsspital Basleland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kantonsspital Baselland
Liestal, Basel-Landschaft, Switzerland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Switzerland
References
Explore related publications, articles, or registry entries linked to this study.
Leuppi JD, Miedinger D, Chhajed PN, Buess C, Schafroth S, Bucher HC, Tamm M. Quality of spirometry in primary care for case finding of airway obstruction in smokers. Respiration. 2010;79(6):469-74. doi: 10.1159/000243162. Epub 2009 Sep 26.
Reference Type
BACKGROUND
Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847-52. doi: 10.1136/thorax.57.10.847.
Reference Type
BACKGROUND
Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007 Jun;101(6):1305-12. doi: 10.1016/j.rmed.2006.10.012. Epub 2006 Nov 16.
Reference Type
BACKGROUND
Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000 Jul 27;343(4):269-80. doi: 10.1056/NEJM200007273430407. No abstract available.
Reference Type
BACKGROUND
Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax. 2006 Mar;61(3):250-8. doi: 10.1136/thx.2005.041822.
Reference Type
BACKGROUND
Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008 Nov 27;359(22):2355-65. doi: 10.1056/NEJMra0800353. No abstract available.
Reference Type
BACKGROUND
Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, Pandey RM. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010 Apr;15(3):536-42. doi: 10.1111/j.1440-1843.2010.01722.x.
Reference Type
BACKGROUND
Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Muller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013 Jun 5;309(21):2223-31. doi: 10.1001/jama.2013.5023.
Reference Type
BACKGROUND
Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980 Jun;92(6):753-8. doi: 10.7326/0003-4819-92-6-753.
Reference Type
BACKGROUND
Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest. 1989 Mar;95(3):563-7. doi: 10.1378/chest.95.3.563.
Reference Type
BACKGROUND
Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med. 1996 Mar;14(2):139-43. doi: 10.1016/S0735-6757(96)90120-5.
Reference Type
BACKGROUND
Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):407-12. doi: 10.1164/ajrccm.154.2.8756814.
Reference Type
BACKGROUND
Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003 Jun 26;348(26):2618-25. doi: 10.1056/NEJMoa023161.
Reference Type
BACKGROUND
Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999 Jun 24;340(25):1941-7. doi: 10.1056/NEJM199906243402502.
Reference Type
BACKGROUND
Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999 Aug 7;354(9177):456-60. doi: 10.1016/s0140-6736(98)11326-0.
Reference Type
BACKGROUND
Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003 Aug;124(2):459-67. doi: 10.1378/chest.124.2.459.
Reference Type
BACKGROUND
Miravitlles M, Mayordomo C, Artes M, Sanchez-Agudo L, Nicolau F, Segu JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med. 1999 Mar;93(3):173-9. doi: 10.1016/s0954-6111(99)90004-5.
Reference Type
BACKGROUND
Walsh LJ, Lewis SA, Wong CA, Cooper S, Oborne J, Cawte SA, Harrison T, Green DJ, Pringle M, Hubbard R, Tattersfield AE. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med. 2002 Sep 1;166(5):691-5. doi: 10.1164/rccm.2110047.
Reference Type
BACKGROUND
Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994 Jul;150(1):11-6. doi: 10.1164/ajrccm.150.1.8025735.
Reference Type
BACKGROUND
Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8.
Reference Type
BACKGROUND
Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007 Sep 1;370(9589):741-50. doi: 10.1016/S0140-6736(07)61377-4.
Reference Type
BACKGROUND
Jochmann A, Scherr A, Jochmann DC, Miedinger D, Torok SS, Chhajed PN, Tamm M, Leuppi JD. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly. 2012 Apr 5;142:w13567. doi: 10.4414/smw.2012.13567. eCollection 2012.
Reference Type
BACKGROUND
Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196-204. doi: 10.7326/0003-4819-106-2-196.
Reference Type
BACKGROUND
Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000 May;117(5 Suppl 2):398S-401S. doi: 10.1378/chest.117.5_suppl_2.398s.
Reference Type
BACKGROUND
Urwyler P, Boesing M, Abig K, Cattaneo M, Dieterle T, Zeller A, Bachler H, Markun S, Senn O, Merlo C, Essig S, Ullmer E, Rutishauser J, Schuurmans MM, Leuppi JD. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial). Trials. 2019 Dec 16;20(1):727. doi: 10.1186/s13063-019-3856-8.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.goldcopd.org
8\. The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KSBL2015-017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD
NCT02330952
COMPLETED
PHASE4
Evaluation Of The Efficacy Of Corticosteroids In Patients With An Acute Exacerbation Of Chronic Obstructive Pulmonary Disease Receiving Ventilator Support
NCT01281748
TERMINATED
PHASE4
Withdrawal of Inhaled Corticosteroids in Primary Care Patients With COPD
NCT02691988
UNKNOWN
NA
Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD
NCT01213693
COMPLETED
NA
Effect of Inhaled Steroids on Gene Expression in the Lungs - 2
NCT00826748
TERMINATED
PHASE4
The Doses of Systemic Steroid in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
NCT01215825
COMPLETED
Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange
NCT00568347
COMPLETED
Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation
NCT01431911
COMPLETED
Effect of Steroids on Gene Expression in the Healthy Smokers Lungs
NCT00532584
WITHDRAWN
PHASE4
Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPD
NCT02209974
COMPLETED
PHASE4
Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care
NCT00440687
COMPLETED
PHASE4
Steroid Resistance During COPD Exacerbations With Respiratory Failure
NCT03680495
UNKNOWN
Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
NCT01353235
COMPLETED
PHASE3
Enhancement of in-Vitro GC Function in Patients With COPD
NCT00241631
COMPLETED
PHASE2
Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels
NCT05059873
TERMINATED
PHASE4
Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis
NCT00524095
TERMINATED
PHASE2
Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)
NCT00387036
TERMINATED
PHASE2
A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)
NCT04441788
TERMINATED
PHASE2
Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00783250
TERMINATED
PHASE4
Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
NCT06892210
NOT_YET_RECRUITING
PHASE4
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00239473
COMPLETED
PHASE3
Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation
NCT04234360
RECRUITING
PHASE3
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01009463
COMPLETED
PHASE3
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01205269
COMPLETED
PHASE2